{"ticker": {"uuid": "6c317cc7-90f7-4370-b7d0-abc75a3227ae", "symbol": "IPH", "name": "Innate Pharma S.A.", "exchange": "PAR", "country": "FR", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Innate Pharma (Nasdaq: IPHA) outlines 2026 AGM quorum and key pipeline focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPcWdTMU1reTdidk16TDRPUG1CbE1tdmhWeFZmdU1jZlNtd21ZNVBqYUE4Z2FyVldHUGY4MXBJQ1R3SDhKb3JoQ20xbVY5T1JiVno0N1pEOUdnb1dNMU9SbTl4TjY1Y0RZeEFaU2ktZzhCTkhWa3dzUlFSUU5JNnNJVEpBYWhTV0gzX0pCbGFZcmRpaHNLMnc4akFGSk5uampSdVRQaUJqUUNlSmZPRnVvOWdB?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma (Nasdaq: IPHA) to meet investors at Jefferies Global Healthcare Conference 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPSGxSMDJ3Q0VKQnkwMXlXT3k4cGxsZUpzaXpia3VMSmxxUWtjbk9NN1hHc0VldGVNckRrdTdaMlh5MTZoYm9mdmNTcDgtdGZud1NtVWZOc0dPbWV5NlNDcmdqQVlxcWwyTF9yR0FmNUt3OXh0blV0TEpEd2R2bGM5YnVodjE1RDE1d1cwa2p1SGZaYkIxRmdrVmQ5dVZlSXRvbzNLVHppNFNqc2pfWXNwR1V3?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma Reports First Quarter 2026 Business Update and Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxNZXZwQW4wX0U2dU5PVU4yMGtadVVIdU8wOGxJVzBMNVR0bDhlVG9ra2llaS1TZ21fR3BXMjB5NGE4MkpiN3VIanZjUG1KbFZCdTlkcDVocXRCa1k0OGhNcWhnZUY1MlBJaFE0bk9YYkRIc1lOR19oMVo0WlZCTmU0WWp0RXB3bG1MNld0RkU1Sng1bXdfbDh3My01UmsxRTJWSDYyYTIzazZwQ3lWSV95NWJINkFqRUFOa190aGo1OXlCeHYyTmZSX3NkcXVmeGxk?oc=5", "source_name": "Business Wire", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma (Nasdaq: IPHA) details Q1 2026 cash runway and trial plans", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxON05HR1lvd280dWU2aHdnYmFYdnNNMElKZk5faVo5SVR0SEJPWnEzYjVxWWpYcjgtaHpNX1lKV2FyMjRYVzBIOXNLRzU1c1N2SldDZWgxanZ1RTBtWW5wUER5NFhfdzJlaTl2Um1tMl9NZnZzdGE0WEdzOFVyQTQ2RXIwcU1wdVRnV3h5WHFyWC1jNF9hdU5wT3dtV0VLTloxVVBXSjJLUFZxOFpOWi1wbEZ3?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of Shares and Voting Rights of Innate Pharma as of April 16, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxPTU8wZ0ktbVRXUlVWdVlSYVJHcmNVenIxeEZMRm1mVzFITWJ5bTc3SVRLcE1adDJTaWZjcHpxdUVSMnpnNEE3Q0FoazNsV3QwTk9rSlVyTXBjeV9CN3lzdFF5T19fTHNDdFR1VDdxU0x2QTYyek02UFgxZVhnNFpoSnh6Z0ZFWmE2TGw5WFdiYTBFU3lYWHZGREQxRVNpcUNxTzI2d3lfNlNwOVJBTFpEMDVjMGlKZTU1V0ZUaU1jOXRyaXNVQ2hB?oc=5", "source_name": "Business Wire", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma (Nasdaq: IPHA) details April 2026 share and voting rights", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQTEVjcHdGQmZ1Y2k2eHRCNlk4TWFsOFlRRzhHTHA1akNjbldhS0FHU1ZHWDZqNHFJTUl1dkQ4NFRhcWZJNmI3NDlLc0ZvelVTa2xOWkEwNS1Ua0hMNmI1LVo3TGVaV0tNeExJa3VsOWpmVWhwNUZucnREdGtYVHo1dW9hZVg5d2xaRVR4QmtBdmQ5MGd6bk8zZEw1RElRcm51SVRZRDhBcnlPdU9LelZONDFR?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Innate Pharma (Nasdaq: IPHA) outlines 2026 AGM quorum and key pipeline focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPcWdTMU1reTdidk16TDRPUG1CbE1tdmhWeFZmdU1jZlNtd21ZNVBqYUE4Z2FyVldHUGY4MXBJQ1R3SDhKb3JoQ20xbVY5T1JiVno0N1pEOUdnb1dNMU9SbTl4TjY1Y0RZeEFaU2ktZzhCTkhWa3dzUlFSUU5JNnNJVEpBYWhTV0gzX0pCbGFZcmRpaHNLMnc4akFGSk5uampSdVRQaUJqUUNlSmZPRnVvOWdB?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma (Nasdaq: IPHA) to meet investors at Jefferies Global Healthcare Conference 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPSGxSMDJ3Q0VKQnkwMXlXT3k4cGxsZUpzaXpia3VMSmxxUWtjbk9NN1hHc0VldGVNckRrdTdaMlh5MTZoYm9mdmNTcDgtdGZud1NtVWZOc0dPbWV5NlNDcmdqQVlxcWwyTF9yR0FmNUt3OXh0blV0TEpEd2R2bGM5YnVodjE1RDE1d1cwa2p1SGZaYkIxRmdrVmQ5dVZlSXRvbzNLVHppNFNqc2pfWXNwR1V3?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma Reports First Quarter 2026 Business Update and Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxNZXZwQW4wX0U2dU5PVU4yMGtadVVIdU8wOGxJVzBMNVR0bDhlVG9ra2llaS1TZ21fR3BXMjB5NGE4MkpiN3VIanZjUG1KbFZCdTlkcDVocXRCa1k0OGhNcWhnZUY1MlBJaFE0bk9YYkRIc1lOR19oMVo0WlZCTmU0WWp0RXB3bG1MNld0RkU1Sng1bXdfbDh3My01UmsxRTJWSDYyYTIzazZwQ3lWSV95NWJINkFqRUFOa190aGo1OXlCeHYyTmZSX3NkcXVmeGxk?oc=5", "source_name": "Business Wire", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma (Nasdaq: IPHA) details Q1 2026 cash runway and trial plans", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxON05HR1lvd280dWU2aHdnYmFYdnNNMElKZk5faVo5SVR0SEJPWnEzYjVxWWpYcjgtaHpNX1lKV2FyMjRYVzBIOXNLRzU1c1N2SldDZWgxanZ1RTBtWW5wUER5NFhfdzJlaTl2Um1tMl9NZnZzdGE0WEdzOFVyQTQ2RXIwcU1wdVRnV3h5WHFyWC1jNF9hdU5wT3dtV0VLTloxVVBXSjJLUFZxOFpOWi1wbEZ3?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of Shares and Voting Rights of Innate Pharma as of April 16, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxPTU8wZ0ktbVRXUlVWdVlSYVJHcmNVenIxeEZMRm1mVzFITWJ5bTc3SVRLcE1adDJTaWZjcHpxdUVSMnpnNEE3Q0FoazNsV3QwTk9rSlVyTXBjeV9CN3lzdFF5T19fTHNDdFR1VDdxU0x2QTYyek02UFgxZVhnNFpoSnh6Z0ZFWmE2TGw5WFdiYTBFU3lYWHZGREQxRVNpcUNxTzI2d3lfNlNwOVJBTFpEMDVjMGlKZTU1V0ZUaU1jOXRyaXNVQ2hB?oc=5", "source_name": "Business Wire", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innate Pharma (Nasdaq: IPHA) details April 2026 share and voting rights", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQTEVjcHdGQmZ1Y2k2eHRCNlk4TWFsOFlRRzhHTHA1akNjbldhS0FHU1ZHWDZqNHFJTUl1dkQ4NFRhcWZJNmI3NDlLc0ZvelVTa2xOWkEwNS1Ua0hMNmI1LVo3TGVaV0tNeExJa3VsOWpmVWhwNUZucnREdGtYVHo1dW9hZVg5d2xaRVR4QmtBdmQ5MGd6bk8zZEw1RElRcm51SVRZRDhBcnlPdU9LelZONDFR?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 76, "total_relevant": 6, "sentiment_summary": {"positive": 0, "negative": 0, "neutral": 6, "score": 50, "total": 6, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 73, "events": [{"event": "general", "label": "Market update", "weight": 2.2, "count": 4}, {"event": "earnings", "label": "Earnings", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 0, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 1.61, "latest_week": "2026-06-19", "one_week_move": 2.9, "four_week_move": -2.0, "twelve_week_move": 46.2, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.815451, "market_dynamics_buy_signal": false, "relative_strength": -1.897476, "fair_value_gap": -18.2, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 47.5722, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+2.9% over one week, -2.0% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 56, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 4}, {"label": "Business Wire", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 6}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 4}, {"label": "Earnings", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "73/100 classification confidence."}, {"label": "Company focus", "value": "6", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+2.9% over one week, -2.0% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Innate Pharma (Nasdaq: IPHA) outlines 2026 AGM quorum and key pipeline focus"}], "updated_at": "2026-06-22T21:06:28.259110+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}